How India Exports Bortezomib to the World

In the United States, Bortezomib is approved under the brand name Velcade. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of Bortezomib, indicating a competitive market landscape. The regulatory pathway for Bortezomib involves rigorous evaluation of bioequivalence and manufacturing standards to ensure safety and efficacy. Given that 25.4% of India's Bortezomib exports are directed to the U.S., Indian manufacturers must adhere strictly to FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and timely reporting of any adverse events.

In the European Union, Bortezomib received marketing authorization under the brand name Velcade on April 26, 2004. Subsequently, generic versions, such as Bortezomib Sun, were approved on July 22, 2016. The European Medicines Agency (EMA) mandates that manufacturers comply with EU Good Manufacturing Practice (GMP) guidelines, ensuring consistent product quality and safety. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and monitoring of Bortezomib, aligning with EMA standards. Indian exporters targeting these markets must obtain the necessary marketing authorizations and demonstrate compliance with GMP requirements.

Bortezomib is included in the 23rd edition of the WHO Model List of Essential Medicines, published in July 2023. This inclusion underscores its critical role in treating multiple myeloma globally. While Bortezomib is not listed under the WHO Prequalification Programme, it must meet stringent quality standards as outlined in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards is essential for manufacturers to ensure global acceptance and marketability of their products.

In India, Bortezomib is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for Bortezomib, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) to ensure that domestic supply is not adversely affected. Manufacturers must also comply with the Central Drugs Standard Control Organization (CDSCO) regulations, including obtaining necessary export licenses and adhering to quality standards.

The primary patents for Bortezomib have expired, leading to increased generic competition globally. This has resulted in a more competitive market, with multiple manufacturers producing generic versions, thereby reducing prices and increasing accessibility. Indian pharmaceutical companies have capitalized on this opportunity, becoming significant players in the global Bortezomib market.

In November 2024, the EMA adopted a positive opinion for Sarclisa (isatuximab) in combination with Bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant. This development may influence the demand for Bortezomib in combination therapies.

In July 2023, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Bortezomib, highlighting its continued importance in global health.

In April 2024, the NPPA conducted a review of anti-cancer drug prices, including Bortezomib, to assess market dynamics and ensure affordability. While no price ceiling was imposed, the review emphasized the need for price monitoring to prevent exorbitant pricing.

In December 2024, the CDSCO issued revised guidelines for the export of pharmaceutical products, streamlining the NOC process to facilitate faster approvals for manufacturers, including those exporting Bortezomib.

In February 2025, the FDA issued a warning letter to an Indian manufacturer of Bortezomib, citing deviations from cGMP regulations. This underscores the importance of maintaining stringent quality control measures to ensure compliance with international standards.

These developments reflect the dynamic nature of the pharmaceutical industry and the need for continuous monitoring of regulatory changes, market trends, and compliance requirements to maintain a competitive edge in the global Bortezomib market.

India's pharmaceutical industry, including the production of Bortezomib, heavily relies on imports of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) from China. Approximately 70% of APIs used in India are sourced from China, underscoring a significant dependency that poses risks to the supply chain. This reliance has been highlighted during various disruptions, such as the COVID-19 pandemic, which led to supply chain interruptions and emphasized the need for self-sufficiency in API production.

In response, the Indian government launched the Production Linked Incentive (PLI) scheme in 2021 to promote domestic manufacturing of critical APIs and KSMs. The scheme targets 53 essential molecules, aiming to reduce import dependence and bolster local production capabilities. (pharmanow.live) However, the transition to self-reliance is gradual, and the industry continues to face challenges in establishing a robust domestic supply chain for APIs like Bortezomib.

The export market for Bortezomib from India is notably concentrated, with the top five exporters accounting for 74.4% of total exports. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 32.0% share, followed by EUGIA PHARMA SPECIALITIES LIMITED (18.4%), MSN LABORATORIES PRIVATE LIMITED (16.4%), VENUS REMEDIES LIMITED (4.0%), and FRESENIUS KABI ONCOLOGY LIMITED (3.7%). This high concentration indicates a significant single-source risk, where disruptions affecting these key players could impact global supply.

The PLI scheme has incentivized companies to invest in domestic API production, with several new plants inaugurated to manufacture essential components. For instance, two greenfield plants were launched in November 2024 to produce Penicillin G and 6-APA, aiming to reduce import dependence by 50%. While these efforts are commendable, the full impact on reducing supplier concentration in the Bortezomib market remains to be seen.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt supply chains. Such disruptions can lead to delays and increased costs in the transportation of pharmaceutical products like Bortezomib. Additionally, trade tensions between major economies, such as the United States and China, have the potential to impact the availability and pricing of APIs and KSMs.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various drugs in the past, often linked to supply chain vulnerabilities. While specific alerts for Bortezomib have not been highlighted recently, the interconnected nature of global pharmaceutical supply chains means that disruptions in one area can have cascading effects, emphasizing the need for proactive risk management strategies.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Invest in Domestic Manufacturing: Leverage government incentives like the PLI scheme to establish or expand local production facilities for critical components.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the flow of materials and identify potential bottlenecks or vulnerabilities.

• Develop Contingency Plans: Establish protocols to address potential disruptions, including alternative sourcing strategies and inventory management practices.

• Monitor Geopolitical Developments: Stay informed about international relations and trade policies that could impact supply chains, allowing for timely adjustments to sourcing and logistics strategies.

RISK_LEVEL: MEDIUM